Equities

Aquestive Therapeutics Inc

AQST:NMQ

Aquestive Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.84
  • Today's Change-0.155 / -3.11%
  • Shares traded1.05m
  • 1 Year change+187.80%
  • Beta2.6340
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments242728
Total Receivables, Net8.474.7012
Total Inventory6.775.784.04
Prepaid expenses1.852.133.08
Other current assets, total------
Total current assets414047
Property, plant & equipment, net9.749.307.78
Goodwill, net------
Intangibles, net1.281.440.05
Long term investments------
Note receivable - long term4.005.006.00
Other long term assets1.441.450.90
Total assets575762
LIABILITIES
Accounts payable8.939.958.31
Accrued expenses6.898.229.64
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.02192.03
Other current liabilities, total2.472.661.99
Total current liabilities184022
Total long term debt283352
Total debt285254
Deferred income tax------
Minority interest------
Other liabilities, total11810371
Total liabilities164176144
SHAREHOLDERS EQUITY
Common stock0.070.060.04
Additional paid-in capital213193175
Retained earnings (accumulated deficit)(319)(311)(257)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(106)(119)(82)
Total liabilities & shareholders' equity575762
Total common shares outstanding695541
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.